Halper Sadeh LLC Encourages Twist Bioscience Corporation Shareholders to Contact the Firm to Discuss Their Rights

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether certain officers and directors of Twist Bioscience Corporation (NASDAQ: TWST) breached their fiduciary duties to shareholders. If you currently own Twist stock and are a long-term shareholder, you may be able to seek corporate governance reforms, the return of funds back to the company, a court-approved financial incentive award, or other relief and benefits. Please click here to learn more about.

Business Wire • Dec 12, 2025

Twist Bioscience Launches New Plasmid Preps to Enable Nucleic Acid Therapeutics Research

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a mid-cap growth and value biotech company, today launched research-grade Plasmid DNA Preps designed to support the advancement of pharmaceutical and biotech customers' pre-clinical studies. “Our new plasmid preps combine the quality and consistency needed for preclinical research with the speed and cost efficiency customers have come to expect from Twist,” said Emily M. Leproust, CEO and co-founder of Tw.

Business Wire • Dec 4, 2025

Kuehn Law Encourages Investors of Twist Bioscience Corporation to Contact Law Firm

NEW YORK, Dec. 03, 2025 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of  Twist Bioscience Corporation (NASDAQ: TWST) breached their fiduciary duties to shareholders.

GlobeNewsWire • Dec 3, 2025

Twist Bioscience Is Bent, Not Broken: Near-Term Strain, Long-Term Strength

Twist's revenue growth continues to moderate due to macro headwinds and temporary challenges in the NGS business. The Biopharma segment is reaccelerating, though, driven by AI-enabled drug discovery customers, and NGS growth will rebound in FY27, driven by MRD customers. Twist's margins also continue to improve, and the company should start to generate positive cash flows within the next 1-2 years.

Seeking Alpha • Nov 18, 2025

Can Twist Bioscience Drop More?

Twist Bioscience (TWST) stock has decreased by 10.1% in one day. The recent downturn signifies renewed worries regarding wider-than-anticipated losses and ambiguous profitability guidance, but significant drops like this often prompt a more challenging question: is this weakness merely temporary, or does it indicate more profound issues in the narrative?

Forbes • Nov 17, 2025

Twist Bioscience Corporation (TWST) Q4 2025 Earnings Call Transcript

Twist Bioscience Corporation (TWST) Q4 2025 Earnings Call Transcript

Seeking Alpha • Nov 14, 2025

Twist Bioscience Announces Fiscal 2025 Fourth Quarter and Full Year Financial Results

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a mid-cap growth and value biotech company, today announced financial results and business highlights for the fourth quarter and full year fiscal 2025 ended September 30, 2025. Visit the Events and Presentations page of the Investor Relations section under the “Company” tab at www.twistbioscience.com to view the detailed fiscal fourth quarter and full year 2025 earnings report and the investor presentatio.

Business Wire • Nov 14, 2025

Top Wall Street Forecasters Revamp Twist Bioscience Expectations Ahead Of Q4 Earnings

Twist Bioscience Corporation (NASDAQ: TWST) will release fourth-quarter earnings before the opening bell on Friday, Nov. 14.

Benzinga • Nov 14, 2025

Twist Bioscience Eyes Profit Turnaround In 2026 After Narrowing Losses

Twist Bioscience Corporation (NASDAQ: TWST) on Friday posted mixed fourth-quarter results, reporting a loss of 45 cents per share, slightly wider than the consensus estimate of a 43-cent loss.

Benzinga • Nov 14, 2025

Twist Bioscience (TWST) Reports Q4 Loss, Tops Revenue Estimates

Twist Bioscience (TWST) came out with a quarterly loss of $0.45 per share versus the Zacks Consensus Estimate of a loss of $0.4. This compares to a loss of $0.59 per share a year ago.

Zacks Investment Research • Nov 14, 2025